Lilly to sell legacy antibiotics brands and manufacturing facility in China24 Apr 2019
Eddingpharm to pick up Ceclor and Vancocin and manufacturing facility.
Eli Lilly has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor and Vancocin, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company.
Under the terms of the agreement, Lilly will receive a deposit of $75 million, followed by a payment of $300 million upon successful closing of the transaction. As part of the transaction, all employees at the Ceclor manufacturing facility and certain employees from shared functions will be offered the opportunity to remain at the facility and continue to work with Eddingpharm. Lilly will provide ongoing services to Eddingpharm for a period of time to ensure continuity of product supply and support the smooth transition of the facility.
"Lilly remains committed to improving the health of people in China," said Julio Gay-Ger, President and General Manager of Lilly China. "This transaction will enable Lilly China to better focus our resources on the exciting new therapies that we are launching in our core therapeutic areas, so that we can bring more life-changing medicines to patients in China."
Mr Xin Ni, CEO of Eddingpharm, said: "Ceclor and Vancocin have been on the Chinese market for more than two decades, treating numerous patients and earning the trust of patients and physicians alike. We are very proud to acquire these two brands and to carry on their legacy. We look forward to maintaining high standards of operation, supplying products with the best quality, and serving more patients in need in China."
The transaction is expected to close in either the latter part of 2019 or early 2020, subject to customary closing conditions and regulatory approval. The transaction will not be reflected in Lilly's reported results and financial guidance until closing.
Improving gut health with human milk oligosaccharides
17 May 2019
2’-FL a very promising agent for digestive health across various age groups beyond infancy.Read more
Expert forecasts huge growth in Middle East manufacturing
16 May 2019
UAE consumers and insurance companies are willing to pay for highest quality drug products.Read more
Colorcon's breakthrough for direct compression
15 May 2019
New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.Read more
Legacy plans for lyophilisation boom
14 May 2019
The increase in biologics is driving the growth in demand for lyophilization in vials.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Catalent achieves global ISO accreditation
12 May 2019
Company is one of the first CDMOs to receive award.Read more
Vibalogics increases capacity with a new 200-L line for virus manufacturing
9 May 2019
Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.Read more
New SIMCA 16 software for multivariate data analytics
8 May 2019
Makes model data easier to interpret for better process control.Read more
Recipharm launches its end-to-end inhalation offering
7 May 2019
Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.Read more
Accessible online courses designed to improve tablet compression tooling
7 May 2019
I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation